Status:
RECRUITING
Evaluation of a Screening Strategy of Fabry Disease in Patient With Renal Biopsy
Lead Sponsor:
University Hospital, Angers
Conditions:
Renal Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Fabry disease is genetic X linked disease, with annual incidence of 1 in 100,000 that is certainly underestimate the true prevalence of the disease. Renal biopsy in some patients does not allow deter...
Eligibility Criteria
Inclusion
- Adult patient (\> 18 years old)
- Obtaining consent to participate in the study
- Patients whose clinical presentation meets at least one of the following criteria:
- Undetermined nephropathy despite renal biopsy,
- Nephroangiosclerosis as the predominant lesion
- Chronic tubulointerstitial nephropathy,
- Glomerulosclerosis,
- Segmental and focal hyalinosis.
- Optically normal kidney or seat of minimal lesions
Exclusion
- Patient who has already been screened for Fabry Disease
- At least one of the following criteria:
- Nephrotic syndrome and/or Glomerular nephropathy
- Histological diagnosis of certain nephropathies (specific kidney lesions)
Key Trial Info
Start Date :
February 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 2 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03869554
Start Date
February 3 2020
End Date
August 2 2025
Last Update
June 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers
Angers, France